Hilal Zıvalı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hilal Zıvalı has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Buğra Aksel
Karadeniz Technical University
2 shared publications - Begüm Nurpelin Sağlık
Department of Pharmaceutical Chemistry, Faculty of Pharmacy Anadolu University Eskisehir Türkiye
2 shared publications - Ezgi Pehlivanlar Yavrucu
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye
2 shared publications - Hasan Erdinç Sellitepe
Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
2 shared publications - İnci Selin Doğan
Department of Pharmaceutical Chemistry Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
2 shared publications - Kutsal Özcan
Department of Pharmaceutical Technology, Faculty of Pharmacy Karadeniz Technical University Trabzon Türkiye
1 shared publication
Latest Publications
- Open Access
- 15 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
From Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors
Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.
- 15 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
Open AccessFrom Fragments to Function: Novel Hydrazone Derivatives as Monoamine Oxidase Inhibitors
Monoamine oxidase (MAO) catalyzes the breakdown of neurotransmitters, including serotonin, dopamine, and norepinephrine. There are two isoforms of this enzyme: MAO‐A and MAO‐B. MAO efficacy is widely investigated in neurodegenerative (MAO‐B) and depressive (MAO‐A) disorders. Upon examining the structures of known inhibitors, it becomes evident that many share an aliphatic amine structure. Furthermore, the literature suggests that compounds with naphthalene skeletons, phenolic structures, and hydrazone moieties exhibit MAO inhibitory activity. In this study, 12 N ‐acylhydrazone derivatives ( 5a–f , 6a–f ) were designed using ligand‐based design methods. Based on biological activity studies, the MAO‐A inhibition of the compounds was calculated to be 0.073–2.54 µM, and the MAO‐B inhibition was 0.064–3.147 µM. Among all compounds, the derivatives bearing a naphthalene ring ( 5d – f , 6d – f ) exhibited MAO enzyme inhibition at levels comparable to those of the reference compounds. The compound with the highest activity, 6e , had IC 50 values of 0.073 ± 0.002 and 0.064 ± 0.002 µM against MAO‐A and MAO‐B, respectively. Due to its superior potency against human MAO‐B, enzyme kinetic studies were further conducted on compound 6e . Consequently, the pronounced inhibitory potency, reversible competitive kinetics, and favorable pharmacokinetic profile of compound 6e designate it as a strong lead candidate for advanced preclinical evaluation.
- 14 July 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (1) , e70347
Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B
Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.
- 14 July 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (1) , e70347
Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B
Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.